AI Article Synopsis
- Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by blood clots in small vessels, linked to various factors like pregnancy and infections, and can have a high mortality rate even with treatment.
- A study aims to develop a specific dental treatment plan for patients with TTP, focusing on periodontal disease and decay based on two patient cases.
- The cases suggest a potential link between TTP and dental issues, highlighting the need for thorough evaluation and treatment of dental problems to reduce TTP recurrences and improve patient outcomes.
Article Abstract
Objectives: Thrombotic thrombocytopenic purpura (TTP) is a rare haematological disease of unknown aetiology. This thrombotic microangiopathy is characterized by microvascular lesions with platelet aggregation. It is found in adults and can be associated with pregnancy, cancer, autoimmune diseases, bone marrow transplantation, drugs and bacterial as well as viral infections. The therapy requires a multi-disciplinary team approach involving dentistry. Even if TTP is immediately treated in an adequate manner, it still shows a mortality of up to 20%.
Aim: To define a specific treatment concept for periodontal disease and decayed teeth in patients suffering from TTP based on the experiences gained from two cases.
Conclusion: The two patient cases revealed a possible association of TTP with dental foci. Because of the severity and mortality of this disease, both prognosis evaluation and treatment standards of periodontologically compromised or decayed teeth have to be strictly followed in patients suffering from TTP. In order to avoid recurrence of TTP, it seems important to remove radically teeth of questionable prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-051X.2004.00617.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rituximab in Immune-mediated thrombotic thrombocytopenic purpura.
Eur J Intern Med
January 2025
Laboratory of Pathology, Hebei Medical University, No. 361, Zhongshan Eastern Road, Shijiazhuang 050000, China. Electronic address:
Plasma Exchange and N-Acetylcysteine Therapy in a Case of Congenital Thrombotic Thrombocytopenic Purpura Presenting With Acute Renal Failure.
J Pediatr Hematol Oncol
January 2025
Departments of Pediatric Hematology.
Congenital thrombotic thrombocytopenic purpura (cTTP), which is associated with mutations in the gene for a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 (ADAMTS13), is a chronic and lifelong disease. The clinical course is variable. Regularly using ADAMTS13-containing products such as fresh frozen plasma (FFP) for long-term prophylaxis is the most important treatment to prevent thrombotic microangiopathy (TMA) episodes.
View Article and Find Full Text PDFThrombotic Thrombocytopenic Purpura Masked by Severe Preeclampsia: A Case Report.
Cureus
November 2024
Hematology and Oncology, King Saud Medical City, Riyadh, SAU.
Thrombotic thrombocytopenic purpura (TTP) is an exceptionally rare complication during pregnancy and even rarer when it coincides with severe preeclampsia in the same index pregnancy. We report the case of a 36-year-old female who presented with confusion at 38 weeks of gestation. Although her signs and symptoms strongly suggested severe preeclampsia, she was expected to make a full recovery after an emergency C-section.
View Article and Find Full Text PDFEffect of peripheral blood absolute monocyte count at admission on relapse-free survival in patients with idiopathic thrombotic thrombocytopenic purpura in remission.
Front Med (Lausanne)
December 2024
Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Introduction: Peripheral monocytes have been reported to correlate with clinical outcomes in various types of malignancies. Previous reports have also shown that acute-phase thrombotic thrombocytopenic purpura (TTP) plasma could induce the activation of monocytes. However, the significance of peripheral blood absolute monocyte count (AMC) in idiopathic TTP remains an unanswered question.
View Article and Find Full Text PDFOutcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: A systematic literature review.
Transfus Apher Sci
December 2024
Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA 02210, USA. Electronic address:
Plasma exchange (PE) outcomes in patients with trigger-associated thrombotic microangiopathy (TMA) have not been comprehensively reviewed. Embase and MEDLINE® were searched on 03/14/2022 for English language articles published after 2007, alongside a congress materials search (2019-2022; PROSPERO: CRD42022325170). Studies with patients with trigger-associated TMA (excluding thrombotic thrombocytopenic purpura, 'typical' hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, post-partum TMA, and TMAs with known genetic cause) who received PE or plasma infusion (PI) and reported treatment response (including measures), safety, patient-/caregiver-reported outcomes, or economic burden data were examined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!